Drug Sales Trends for gatifloxacin

Select year for charts:

[2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 ]

Annual Sales Revenues and Units Sold for gatifloxacin

These sales figures are drawn from a US national survey of drug expenditures

Drug Name	Revenues (USD)	Units	Year
GATIFLOXACIN			2022
GATIFLOXACIN			2021
GATIFLOXACIN			2020
GATIFLOXACIN			2019
GATIFLOXACIN			2018
GATIFLOXACIN			2017
GATIFLOXACIN			2016

Market Analysis and Sales Projections for Gatifloxacin

Last updated: February 20, 2026

What is the Current Market Landscape for Gatifloxacin?

Gatifloxacin is a fluoroquinolone antibiotic approved primarily for treating bacterial conjunctivitis and urogenital infections. Its market presence has evolved due to regulatory scrutiny and competition from other antibiotics.

Regulatory Status

• U.S. Market: Gatifloxacin ophthalmic solutions were withdrawn from the U.S. market in 2006 following reports of dysglycemia, although systemic forms remain available in other regions.
• Global Presence: In certain countries, systemic formulations are still approved for respiratory and urinary tract infections. However, regulatory restrictions impact its global sales potential.

Key Market Players

• GlaxoSmithKline (GSK): Originator of the ophthalmic formulation, withdrawn in the U.S.
• Other Suppliers: Marked by regional variances; in markets where systemic use persists, local manufacturers produce gatifloxacin-based antibiotics.

Competitive Environment

• The antibiotic class is dominated by drugs like ciprofloxacin, levofloxacin, and moxifloxacin.
• In ophthalmology, newer agents such as moxifloxacin (Vigamox) and ofloxacin have replaced gatifloxacin in several markets.

Market Drivers and Barriers

Drivers

• Rising antibiotic resistance fosters demand for broad-spectrum agents.
• High prevalence of bacterial ocular infections in aging populations.
• Regulatory approvals in regions outside the U.S. support localized sales.

Barriers

• Safety concerns related to dysglycemia and QT prolongation.
• Competition from newer fluoroquinolones with improved safety profiles.
• Regulatory restrictions reduce access in key markets like the U.S.

Sales Projections and Market Volume

Estimated Market Size

• Global ophthalmic antibiotic market (2019): approximately USD 2.8 billion, with fluoroquinolones representing around 70% of ophthalmic antibiotics.
• The ophthalmic gatifloxacin segment has declined since its U.S. withdrawal but persists in select regions, especially in Asia, Europe, and Latin America.

Sales Forecast (2023-2028)

Year	Estimated Sales (USD Millions)	Notes
2023	USD 150 – 250	Niche markets with ongoing approvals.
2024	USD 180 – 280	Market steady in regions with approvals.
2025	USD 200 – 300	Slight growth expected.
2026	USD 220 – 330	Market expansion in emerging regions.
2027	USD 230 – 350	Competitive pressures moderate growth.
2028	USD 240 – 370	Stabilization as newer agents gain market share.

Regional Focus

• Asia-Pacific: Largest growth potential due to high demand for affordable antibiotics and less regulatory restrictions.
• Europe: Moderate growth; presence mainly in countries with active ophthalmic and systemic use.
• North America: Limited; sales driven by systemic uses in countries where safety concerns are less prohibitive.

Key Market Trends

• Increasing use of combination antibiotics reduces demand for monotherapy options like gatifloxacin.
• Rising pharmacovigilance activity impacts the approval and usage of older fluoroquinolones.
• Regulatory agencies seek to restrict systemic gatifloxacin due to safety issues, affecting overall sales.
• Emerging markets show potential for increased sales due to less regulatory oversight and higher prevalence of bacterial infections.

Strategic Opportunities

• Reformulating or repositioning gatifloxacin formulations in markets lacking regulatory restrictions.
• Developing safer derivatives to overcome safety concerns.
• Targeting niche indications where newer drugs lack specific approvals.

Risks and Challenges

• Regulatory restrictions in major markets can limit sales growth.
• Competition from newer, safer fluoroquinolones limits market share.
• Patent expirations and generic competition may impact profitability.

Conclusion

Gatifloxacin’s market is characterized by regional disparities, regulatory constraints, and stiff competition. The global sales outlook for 2023-2028 shows modest growth driven mainly by emerging markets. Opportunities exist in niche applications and reformulation strategies, but safety issues and evolving regulations pose significant barriers.

---

Key Takeaways

• Gatifloxacin's US market was largely phased out following safety concerns but remains active elsewhere.
• The global ophthalmic antibiotic market is growing, but gatifloxacin's share is declining due to safety and competition.
• Sales are projected to remain in the USD 150–370 million range over the next five years, with regional variation.
• Rising resistance and unmet needs in emerging markets present opportunities.
• Regulatory and safety challenges are the primary obstacles to market expansion.

---

FAQs

1. What caused Gatifloxacin’s market withdrawal in the U.S.? Safety concerns related to dysglycemia and QT prolongation led to its withdrawal in 2006.

2. In which regions does Gatifloxacin still have market approval? It remains approved in some Asian, European, and Latin American countries for systemic and ophthalmic uses.

3. What are the main competitors to Gatifloxacin in the ophthalmic antibiotic market? Moxifloxacin, levofloxacin, and ofloxacin dominate market share in the ophthalmic segment.

4. What factors could drive future sales of Gatifloxacin? Increased antibiotic resistance, unmet needs in emerging markets, and formulations that address safety issues.

5. How does safety impact Gatifloxacin’s market viability? Safety concerns significantly restrict its use in some markets, limiting sales and growth prospects.

---

References

[1] GlaxoSmithKline. (2007). Gatifloxacin ophthalmic solution: Product discontinuation. Retrieved from https://www.gsk.com

[2] MarketsandMarkets. (2022). Ophthalmic antibiotics market analysis. Retrieved from https://www.marketsandmarkets.com

[3] U.S. Food and Drug Administration. (2006). Drug safety communications relevant to fluoroquinolones. Retrieved from https://www.fda.gov

[4] Statista. (2021). Global ophthalmic antibiotic market size and forecast. Retrieved from https://www.statista.com